Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials

Main Article Content

Mark Lebwohl
Linda Stein Gold
Bruce Strober
April Armstrong
H Chih-Ho Hong
Leon Kircik
Jennifer Soung
Jeff Fromowitz
Scott Guenthner
Stephen Piscitelli
David Rubenstein
Philip Brown
Anna Tallman
Robert Bissonnette

Keywords

Psoriasis, Aryl Hydrocarbon Receptor Modulating Agent, Tapinarof, Safety, Efficacy

Abstract

Abstract not available.

References

1. Menter A, et al. J Am Acad Dermatol. 2008;58:826–850

2. Robbins K, et al. J Am Acad Dermatol. 2019;80:714–721

3. Stein Gold L, et al. J Am Acad Dermatol. 2020; doi: 10.1016/j.jaad.2020.04.181.